Table 1.
No. | Kd/Ki | Other targets | Scaffold | Status | Ref. |
---|---|---|---|---|---|
1 | Kd = 4 nMa | Aβ, tau | Benzothiazole | in vitro | [81, 82] |
2 | Kd = 9.63 nMa | Aβ | Benzoxazole | in vivo | [83] |
3 | Kd = 148 nMa, Ki = 57.94 nMb,c | Aβ, tau | Phenothiazine | in vivo | [85, 86] |
4 | Ki = 66.2 nMc,d | Aβ, tau | Phenothiazine | in vivo | [87] |
5 | Ki = 19.9 nMc,d | Aβ, tau | Phenothiazine | in vivo | [87] |
6 | Kd = 8.9 nMa, Ki = 2 nMb,c | Aβ, tau | 3-(benzylidine) indolin-2-one | in vitro | [88] |
7 | Kd = 5.4 nMa | Aβ | Chalcone | in vitro | [89] |
8 | Kd = 99.5 nMa,c | Aβ | Benzoimidazole | in vitro | [90] |
aDetermined by saturation binding assays
bDetermined by ThT competition assays
cIsotope unlabeled
dDetermined by 125I-SIL23 competition assays